IP Library Granted Patent US 8,012,999
Granted Patent B2
US 8,012,999 · App. 12/782,967 · Granted Sep 6, 2011

Modulators of CFTR

Assignee: Vertex Pharmaceuticals Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,012,999
App. No.
12/782,967
Granted
Sep 6, 2011
Kind
B2
Abstract

Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Claims (29)

1. A method of treating or lessening the severity of a disease in a patient, wherein said disease is dry-eye disease, said method comprising the step of administering to said patient an effective amount of a compound according to formula I:

or a pharmaceutically acceptable salt thereof, wherein independently for each occurrence:

m is 0-4;

R M is —Z M R 11 , wherein each Z M is a bond or an optionally substituted branched or straight C 1-6 aliphatic chain wherein up to two carbon units of Z M are optionally replaced by —CO—, —CS—, —CONR N —, —CO 2 —, —OCO—, —NR N CO 2 —, —O—, —OCONR N —, —NR N CO—, —S—, —SO—, —SO 2 —, or —NR N —;

R 11 is R N , halo, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , or —OCF 3 ;

R N is H or an optionally substituted C1-C8 aliphatic;

R 1 is a C1-C6 aliphatic;

R 2 is H or an optionally substituted C1-C6 aliphatic;

R 3 and R′ 3 together with the carbon atom to which they are attached form an unsubstituted C 3-7 cycloalkyl ring; and

R 4 is:

2. The method of claim 1 , wherein R 1 is an optionally substituted C1-C4 aliphatic.

3. The method of claim 1 , wherein R 1 is an optionally substituted C1-C4 alkyl.

4. The method of claim 1 , wherein R 1 is methyl, ethyl, propyl, or butyl.

5. The method of claim 1 , wherein R 2 is H.

6. The method of claim 1 , wherein R 2 is a C1-C6 aliphatic.

7. The method of claim 1 , wherein R 2 is a C1-C6 alkyl.

8. The method of claim 1 , wherein R 2 is methyl, ethyl, propyl, butyl, pentyl, or hexyl.

9. The method of claim 1 , wherein R 3 and R′ 3 taken together form a cyclopropyl ring.

10. The method of claim 1 , wherein R 3 and R′ 3 taken together form a cyclopentyl ring.

11. The method of claim 1 , wherein R 4 is

12. The method of claim 1 , wherein R 4 is

13. The method of claim 1 , wherein m is 0.

14. The method of claim 1 , wherein the compound is according to formula II:

15. The method of claim 14 , wherein R 1 is methyl.

16. The method of claim 14 , wherein m is 0.

17. The method of claim 1 , wherein the compound is according to formula III:

18. The method of claim 17 , wherein R 1 is methyl.

19. The method of claim 17 , wherein m is 0.

20. The method of claim 1 , wherein the compound is

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2016
From: MACQUARIE US TRADING LLC
To: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
Reel/Frame 040357/0001 →
SECURITY INTEREST Recorded Jul 10, 2014
From: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 033292/0311 →
Continuity (5)
Continuation 12117948 · May 9, 2008
Continuation In Part 11804726 · May 18, 2007
Continuation In Part 11594431 · Nov 8, 2006
Provisional Application 60928289 · May 9, 2007
Related Publication 20100227888A1 · Sep 9, 2010